The recent finding that enrichment of peripheral CD8+PD1+ T cell associates with poor overall survival in a cohort of patients affected by metastatic cancer (≈50% HNSCC) and submitted to immune-checkpoint inhibitors [53] may be interpreted as a clinical consequence of the biologic phenomena highlighted by our data. The gene discussed is CD8A; the disease is metastatic malignant neoplasm.